Biorg Med Chem 25:61806189 Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg M, Ramaswamy B, Fowler J, Wei L et al (2019) Phase I immunotherapy trial with two chimeric HER-2 B-cell peptide vaccines emulsified in montanide ISA 720VG and nor-MDP adjuvant in patients with advanced solid tumors phase I immunotherapy trial with two B-cell vaccines
BPC-157 is well-known for its ability to accelerate the healing of tissues like tendons, ligaments, and muscles
The original approved version was discontinued in 2008 for commercial reasons, not safety concerns
As a dual board-certified pain management and anesthesiology physician, Dr
Aggressive handling, like shaking the vial, can shear the peptide bonds, a process called denaturing